Solvay gets co-promotion rights for Simcor

The drug is currently awaiting FDA approval.

Under the terms of the agreement, Solvay will provide sales support in the US, contribute to development and promotional expenses and be compensated based on product sales.

Simcor builds upon an ongoing agreement between Abbott and Solvay involving the commercialization and development of fenofibrate, and continues both companies’ commitment toward the treatment of lipid disorders.

Simcor combines two well-established medications, Niaspan and Simvastatin, to target multiple lipid parameters – LDL ‘bad’ cholesterol, HDL, ‘good’ cholesterol and triglycerides – in a single pill.